Sage therapeutics, inc. (SAGE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Sep'13Jun'13
Total revenue

2,286

1,960

3,570

873

465

-

-

90,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating costs and expenses:
Cost of goods sold

170

-

137

44

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

63,610

91,250

102,108

89,059

86,398

88,805

75,052

68,980

49,270

50,891

58,286

55,900

45,200

42,004

29,075

26,096

23,581

20,376

17,478

18,603

12,900

8,945

6,601

4,381

4,173

3,408

3,854

Selling, general and administrative

70,130

85,129

88,502

88,227

83,919

75,695

53,693

43,167

28,849

19,557

16,087

14,954

12,280

14,375

8,989

8,910

7,133

8,236

6,604

6,456

3,997

3,417

2,869

1,807

1,617

1,111

801

Total operating costs and expenses

133,910

176,598

190,747

177,330

170,317

164,500

128,745

112,147

78,119

70,448

74,373

70,854

57,480

56,379

38,064

35,006

30,714

28,612

24,082

25,059

16,897

12,362

9,470

6,188

5,790

4,519

4,655

Loss from operations

-131,624

-174,638

-187,177

-176,457

-169,852

-164,227

-128,745

-22,147

-78,119

-70,448

-74,373

-70,854

-57,480

-56,379

-38,064

-35,006

-30,714

-28,612

-24,082

-25,059

-16,897

-12,362

-9,470

-6,188

-5,790

-4,519

-4,655

Interest income, net

4,729

5,915

7,227

8,220

6,442

5,851

5,817

5,137

3,529

1,043

677

672

707

495

275

266

175

63

53

41

21

-

3

1

-

-

-

Other income, net

155

70

-8

16

4

-12

10

32

-8

-16

-23

-20

-5

-17

-7

-7

-4

-13

-6

-9

5

-

-1

-5

-

-

-

Net loss

-126,740

-168,653

-179,958

-168,221

-163,406

-158,388

-122,918

-16,978

-74,598

-69,421

-73,719

-70,202

-56,778

-55,901

-37,796

-34,747

-30,543

-28,562

-24,035

-25,027

-16,871

-12,361

-9,468

-6,192

-5,790

-4,519

-4,655

Accretion of redeemable convertible preferred stock to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

391

1,577

326

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-12,361

-9,859

-7,769

-6,116

-4,519

-4,655

Net loss per share—basic and diluted

-2.44

-3.25

-3.48

-3.28

-3.37

-3.41

-2.63

-0.36

-1.68

-1.72

-1.97

-1.88

-1.52

-1.55

-1.15

-1.08

-0.97

-1.00

-0.84

-0.90

-0.66

7.10

-0.50

-4.57

-3.70

-2.98

-3.18

Weighted average number of common shares outstanding—basic and diluted

51,908

51,881

51,704

51,257

48,491

46,910

46,706

46,541

44,325

40,353

37,470

37,361

37,269

37,289

32,975

32,062

31,643

28,859

28,737

27,860

25,655

63,362

19,581

1,700

1,652

1,514

1,464

Comprehensive loss:
Net loss

-126,740

-168,653

-179,958

-168,221

-163,406

-158,388

-122,918

-16,978

-74,598

-69,421

-73,719

-70,202

-56,778

-55,901

-37,796

-34,747

-30,543

-28,562

-24,035

-25,027

-16,871

-12,361

-9,468

-6,192

-5,790

-4,519

-4,655

Other comprehensive items:
Unrealized gain (loss) on marketable securities

-2,087

-482

202

1,681

409

-258

-112

40

-156

-14

52

14

21

-

-74

39

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive gain (loss)

-2,087

-482

202

1,681

409

-258

-112

40

-156

-14

52

14

21

-

-74

39

-

-

-

-

-

-

-

-

-

-

-

Total comprehensive loss

-128,827

-169,135

-179,756

-166,540

-162,997

-158,646

-123,030

-16,938

-74,754

-69,435

-73,667

-70,188

-56,757

-55,968

-37,870

-34,708

-30,543

-

-24,035

-25,027

-

-

-

-

-

-

-

Product Revenue [Member]
Total revenue

2,286

-

1,478

519

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Collaboration Revenue [Member]
Total revenue

-

0

2,092

354

465

-

-

90,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-